SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.35 | $0 | -$15M |
| 2025 Q4 | -2.39 | $0 | -$18M |
| 2025 Q3 | 4.26 | $0 | -$13M |
| 2025 Q2 | -1.09 | $0 | -$7M |
| 2025 Q1 | -0.56 | $0 | -$8M |
| 2024 Q4 | -1.23 | $114,698 | -$9M |
| 2024 Q3 |
| -1.12 |
| $0 |
| -$6M |
| 2024 Q2 | -0.79 | $263,137 | -$8M |